Your SlideShare is downloading. ×
Requirements before biologically derived vaccine administered to patients
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Requirements before biologically derived vaccine administered to patients

170

Published on

The U.S. Food and Drug Administration (FDA), released a report that advocated the Quality-by-design approach of process validation for the pharmaceutical industry. Learn what the new approach means …

The U.S. Food and Drug Administration (FDA), released a report that advocated the Quality-by-design approach of process validation for the pharmaceutical industry. Learn what the new approach means and its potential impact.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
170
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1.  „PharmaceuticalQuality for the 21st Century: A Risk-Based Approach‟ is a FDA report  Quality-by-design approach of process validation for the pharmaceutical industry New approach includes  Process Development, Process Analytical Technologies, and Corrective and Preventive Actions (CAPA)
  • 2.  TheFDA takes a “fragmented” approach to process development  According to compliance specialist Michael R. Goodman from Compliance Insight Goodman: pharmaceutical companies need to prioritize process development Enhance risk-mitigation through intentional and careful review of problems that could develop from internal and external factors
  • 3.  Necessary steps include  Process development  Equipment audit  Targeted research to create supporting documentation for process validation  Quality-by-design – validation  Process analytical technologies (PAT)  Preventative and Corrective Actions
  • 4.  Thefollowing can be achieved with this approach  Mitigating potential risk, maximizing understanding of the process, and establishing in-process controls Purpose: provide scientific and supporting evidence of a controlled process Provide in-depth characterization studies in case of out-of-specification investigation, according to Goodman
  • 5.  Take the issue of determining what the factors are for administrating biologically derived pharmaceuticals to better understand the concept Examples  validated analytical methods;  qualified instruments;  maintenance and calibration programs; change control program;  identification of critical process and parameter markers, with their respective acceptance range;  bio-assays defined and qualified;  defined raw materials;  defined equipment, utilities, and services;  defined process parameters and acceptance range;  standard operating procedures; process documentation;  critical analysis/risk-analysis;  validation master plan; checks and controls for equipment, services, and utilities.
  • 6.  The important factors include  Observing Quality by Design (QbD)  Risk Based Method  Process to undergo Design of Experiments (DOE)  Operational Limits  Purpose of Step  Defining variability range  Perform at lab scale  Potential investigative evidence
  • 7.  Thecomplete deployment of Quality-by- design must include  Every aspect of the ingredients and material including right up to what packaging would be used  Equipment monitoring, maintenance and calibration  Emphasis on the process design and implementation of the most efficient manufacturing process  Critical measures and procedures to ensure and maintain quality at every step
  • 8.  Momentum behind Quality-by-design is a result of the fact that it can produce better pharmaceuticals Requires manufacturers to increase their involvement in drug development and production monitoring Adds cost
  • 9.  Compliance Insight, Inc. Your Hands-On Quality and Regulatory Specialists Our services include GMP consulting, audit preparation, FDA mock inspections, FDA response assistance, vendor/contract audits, GMP training and accreditation, new construction compliance, regulatory consulting, investigations, biosafety and viral testing consulting; clinical trial audits and more. For more information visit http://compliance- insight1.com/

×